Puerto Rico Hurricanes
NHF partners with local HTCs to provide support to the bleeding disorders community in Puerto Rico after the island is devasted by Hurricanes Irma and Maria.
NHF partners with local HTCs to provide support to the bleeding disorders community in Puerto Rico after the island is devasted by Hurricanes Irma and Maria.
The NHF and CDC conducted a survey, completed in March 2000, aimed at ascertaining knowledge about, attitudes toward, and behaviors associated with key prevention activities among people with hemophilia.
In 2000, NHF launched Project Red Flag with program partners from the the Centers for Disease Control and Prevention. The national campaign had the aptly phrased tagline, “real talk about women’s bleeding disorders."
NHF launches a Career Development Award to support and fund researchers.
From September 1999 through February 2000, NHF and CDC conducted a national baseline telephone survey to assess prevention knowledge and health practices in the hemophilia community to inform development of an effective national prevention program. Survey results and knowledge in the field were used to identify priority messages for NHF’s National Prevention Program (NPP). The NPP is a public awareness campaign targeting people affected by bleeding disorders, their families, and health care providers. The NPP’s theme is “Do the 5!,” which includes the following five strategies for living a longer and healthier life:
Get an annual comprehensive checkup at a hemophilia treatment center.
Get vaccinated—hepatitis A and B are preventable.
Treat bleeds early and adequately.
Exercise and maintain a healthy weight to protect your joints.
Get tested regularly for bloodborne infections.
NHF elects its first female board president, Katherine Muir.
NHF launches the "It's Time for a Cure!" campaign.
NHF forms a "Women with Bleeding Disorders Task Force" for the first time.
With the guidance of NHF advocates, Rep. Porter J. Goss of Florida introduces the H.R.1023 - Ricky Ray Hemophilia Relief Fund Act of 1998.
The first factor IX (9) product granted FDA approval.